Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;14(9):2299-2324.
doi: 10.1007/s13346-024-01532-x. Epub 2024 Feb 7.

State of the art in pediatric nanomedicines

Affiliations
Review

State of the art in pediatric nanomedicines

Saba Abedin et al. Drug Deliv Transl Res. 2024 Sep.

Abstract

In recent years, the continuous development of innovative nanopharmaceuticals is expanding their biomedical and clinical applications. Nanomedicines are being revolutionized to circumvent the limitations of unbound therapeutic agents as well as overcome barriers posed by biological interfaces at the cellular, organ, system, and microenvironment levels. In many ways, the use of nanoconfigured delivery systems has eased challenges associated with patient differences, and in our opinion, this forms the foundation for their potential usefulness in developing innovative medicines and diagnostics for special patient populations. Here, we present a comprehensive review of nanomedicines specifically designed and evaluated for disease management in the pediatric population. Typically, the pediatric population has distinguishing needs relative to those of adults majorly because of their constantly growing bodies and age-related physiological changes, which often need specialized drug formulation interventions to provide desirable therapeutic effects and outcomes. Besides, child-centric drug carriers have unique delivery routes, dosing flexibility, organoleptic properties (e.g., taste, flavor), and caregiver requirements that are often not met by traditional formulations and can impact adherence to therapy. Engineering pediatric medicines as nanoconfigured structures can potentially resolve these limitations stemming from traditional drug carriers because of their unique capabilities. Consequently, researchers from different specialties relentlessly and creatively investigate the usefulness of nanomedicines for pediatric disease management as extensively captured in this compilation. Some examples of nanomedicines covered include nanoparticles, liposomes, and nanomicelles for cancer; solid lipid and lipid-based nanostructured carriers for hypertension; self-nanoemulsifying lipid-based systems and niosomes for infections; and nanocapsules for asthma pharmacotherapy.

Keywords: Cancer therapy; Nanomedicines; Nanopharmaceuticals; Nanotechnology; Pediatric drug delivery; Polymeric nanocarriers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lehmann B. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health. 2008;2:37. https://doi.org/10.1186/1753-2000-2-37 . - DOI - PubMed - PMC
    1. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National Institute of Child Health and Human Development-Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012;34:S11–24. https://doi.org/10.1016/j.clinthera.2012.09.014 . - DOI - PubMed - PMC
    1. Avant D, Wharton GT, Murphy D. Characteristics and changes of pediatric therapeutic trials under the Best Pharmaceuticals for Children Act. J Pediatr. 2018;192:8–12. https://doi.org/10.1016/j.jpeds.2017.08.048 . - DOI - PubMed
    1. Ren Z, Zajicek A. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39:530–1. https://doi.org/10.1053/j.semperi.2015.08.006 . - DOI - PubMed - PMC
    1. Turner MA, Catapano M, Hirschfeld S, Giaquinto C. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev. 2014;73:2–13. https://doi.org/10.1016/j.addr.2014.02.003 . - DOI - PubMed

LinkOut - more resources